NFKB1 and mantle cell lymphoma: Several resistance mechanisms associated with bortezomib have been reported in MCL, including activation of NFkB signaling, accumulation of anti-apoptotic protein Mcl-1, and accumulation of casein kinase 2 (CK2, the serine/threonine kinase and activator of STAT3) [76–78].